NRG-GY024 (Vulvar Cancer) - Clinical Trial
¿Cuál es el Propósito de este estudio?
We are doing this study to see if radiation and chemotherapy can be done instead of an extensive surgical removal of the groin lymph nodes for patients with vulvar cancer whose disease has spread to the sentinel node. We are doing this study because we want to find out if this approach is better or worse than the usual approach for vulvar cancer.
¿Cuál es la Condición que se está estudiando?
Early Stage Vulvar Cancer
¿Quién puede participar en el Estudio?
Adult females ages 18+ who:
- Are diagnosed with primary squamous cell carcinoma of the vulva
- Have a T1 tumor that is not encroaching the urethra, vagina, or anus
- Have no enlarged or suspicious lymph nodes found by imaging (CT/MRI/ultrasound)
For more information about who can join this study, please contact the study team at nick.jeffries@duke.edu.
Grupo etario
Adultos
¿Qué Implica?
Si elige unirse a este estudio, podrá:
- Be treated with a higher dose of radiation than what is typically given after surgery
- Receive chemotherapy drugs (cisplatin/carboplatin) once a week during radiation treatment
The radiation + chemotherapy treatment will last for 5 weeks.
After your treatment is finished, you will visit our clinic for check-ups every 3 months for 2 years.
Detalles del Estudio
Título Completo
NRG-GY024: Groningen International Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) III: A Prospective Phase II Treatment Trial.
Investigador Principal
Diandra N. Ayala-Peacock, MD
Especialista en oncología radioterápica
Número de Protocolo
IRB:
PRO00109439
NCT:
NCT05076942
Fase
Phase II
ClinicalTrials.gov
Ver en ClinicalTrials.gov
Estado de inscripción
Abierto para inscripción
Participate
Call 919-684-3780